JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HUGGINS, R. A.
Right arrow Articles by LA FORGE, M.
Right arrow Search for Related Content
PubMed
Right arrow Articles by HUGGINS, R. A.
Right arrow Articles by LA FORGE, M.
Journal of Pharmacology And Experimental Therapeutics, Vol. 95, Issue 3, 312-317, 1949
Copyright © 1949 by American Society for Pharmacology and Experimental Therapeutics

THE PROTECTIVE ACTION OF VARIOUS AGENTS AGAINST CHLOROFORM-EPINEPHRTNE VENTRICULAR FIBRILLATION

R. A. HUGGINS 1, R. A. MORSE 1, C. A. HANDLEY 1, and M. LA FORGE 1

1 Department of Pharmacology, Baylor University College of Medicine

1. Three groups of agents were studied for their prophylactic effect against the production of ventricular fibrillation in barbitalized dogs given epinephrine during chloroform anesthesia.

a. So-called coronary vasodilating agents: sodium nitrite, aminophylline, papaverine, and quinacrine.

b. Agents decreasing myocardial excitability: procaine and quinidine sulfate.

c. Adrenolytic agents: dibenamine and priscol.

2. Criteria for protection against ventricular fibrillation were defined so as to include prevention of increased ventricular excitability preceding fibrillation as well as prevention of fibrillation.

3. Coronary dilating agents afford no protection.

4. Procaine affords no practical protection.

5. Quinidine sulfate affords appreciable and consistent protection.

6. Adrenolytic agents afford complete protection.

7. A pressor response to epinephrine is not necessary for the production of this type of ventricular fibrillation.

Submitted on November 8, 1948






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1949 by the American Society for Pharmacology and Experimental Therapeutics.